Skip to content
Clinical Trial Events
ISPOR Europe 2026

Panel Access and Pricing track

Who Decides Which Covariates Matter? Aligning Regulatory and HTA Perspectives in Indirect Treatment Comparisons

Mon, Nov 9, 2026 · 10:30–11:30 AM CET Hall E1, Level 0, Austria Center Vienna

About this session

ISSUE: Indirect treatment comparisons (ITCs) are essential for health technology assessment (HTA) when head-to-head evidence is unavailable. Advances in methods, including population-adjusted indirect comparison, multilevel network meta-regression, and real-world evidence, have increased the sophistication of comparative effectiveness analyses. However, a persistent challenge remains: which covariates should be included in ITC adjustment models?

Speakers

  • Mikkel Oestergaard

    Merck Sharp & Dohme International Service B.V.

    Moderator

  • Kate Ren

    University of Sheffield

    Panelist

  • Anja Schiel

    Special Advisor, Lead Methodologist; Leader international HTA (iHTA) NoMA · Norwegian Medicines Agency

    Panelist

  • Dominik Karres

    European Medicines Agency

    Panelist